| Patient | David Hume |
|---|---|
| Date of birth | 1711-05-07 |
| Identifiers | MRN HR-EN012-SYN-TD; SSN (made up) 000-12-3049 |
| Document date | 2026-11-01 |
| Author | Fiona Gallacher, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for three months of looser stools with dark blood, tiredness, and weight loss. Concerns: Three months of looser, more frequent stools with dark blood mixed in on several days, tiredness, and about 6 kg of unintended weight loss; Wants plain information about what is wrong and wants to keep working on his books through treatment. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferric carboxymaltose 750 mg intravenous infusion, two doses one week apart | 750 mg IV once a week for two doses | Intravenous route | 1775-06-01 to 1775-06-08 | completed | S |
| Capecitabine 500 mg oral tablet, four tablets (1749 mg, 1000 mg/m²) by mouth twice daily on days 1 to 14 of each 21-day cycle, four cycles | Four tablets twice daily on days 1 to 14 of each 21-day cycle | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Oxaliplatin 130 mg/m² (260 mg) intravenous infusion on day 1 of each 21-day cycle, four cycles | 260 mg IV on day 1 every 21 days | Intravenous route | 1775-07-20 to 1775-09-21 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea during chemotherapy | One tablet every 8 hours as needed for nausea | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than eight a day | As needed for diarrhea on capecitabine | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Colonoscopy to the cecum with biopsy: 4 cm ulcerated, partly circumferential, non-obstructing mass at 28 cm in the sigmoid colon, tattooed; no other lesions. Biopsy: moderately differentiated adenocarcinoma, mismatch-repair proteins (MLH1, PMS2, MSH2, MSH6) intact | 1775-05-19 to 1775-05-19 | completed | S |
| CT of the chest, abdomen, and pelvis with contrast: sigmoid wall thickening with two pericolic lymph nodes up to 7 mm; lungs clear; one 9 mm indeterminate low-density lesion in liver segment VI | 1775-05-21 to 1775-05-21 | completed | S |
| MRI of the liver with contrast: the 9 mm segment VI lesion is a typical hemangioma, with peripheral nodular enhancement and progressive fill-in; no liver metastases | 1775-06-04 to 1775-06-04 | completed | S |
| Laparoscopic sigmoid colectomy with primary anastomosis and no stoma. Pathology: adenocarcinoma, moderately differentiated, pT3 N1a (1 of 22 nodes), margins clear, no lymphovascular or perineural invasion; stage IIIB | 1775-06-16 to 1775-06-16 | completed | S |
| Adjuvant CAPOX chemotherapy, four 21-day cycles (three months), given by medical oncology | 1775-07-20 to 1775-10-04 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1774-10-14 | Influenza vaccine, 1774-1775 season | completed | S |
| 1768-03-12 | Tdap vaccine | completed | S |
| 1775-10-28 | Influenza vaccine, 1775-1776 season | completed | S |
| 1775-10-28 | Pneumococcal conjugate vaccine PCV20 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| September 1729 | Illness from about the age of eighteen, given the contemporary label 'the disease of the learned', with scurvy spots on the fingers, a watery mouth, and later a ravenous appetite and palpitations; treated with bitters, anti-hysteric pills, claret, and daily riding | D (CLM-0003) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died when Hume was an infant; cause not recorded in the cited source | D (CLM-0002) | |
| mother | Died before 1749; a physician's letter of early 1776 reports Hume's statement that she had the same constitution and died of the same bowel disorder, which the source does not describe further | D (CLM-0002, CLM-0005) |
| Concern | Status | Evidence |
|---|---|---|
| Three months of looser, more frequent stools with dark blood mixed in on several days, tiredness, and about 6 kg of unintended weight loss | active | S |
| Wants plain information about what is wrong and wants to keep working on his books through treatment | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 12.1 on 1775-09-08; MCV [Entitic mean volume] in Red Blood Cells by Automated count 89 on 1775-10-19; Leukocytes [#/volume] in Blood by Automated count 4.6 on 1775-09-08; Platelets [#/volume] in Blood by Automated count 156 on 1775-09-08; Ferritin [Mass/volume] in Serum or Plasma 186 on 1775-07-13; Iron saturation [Mass Fraction] in Serum or Plasma 24 on 1775-07-13; Sodium [Moles/volume] in Serum or Plasma 139 on 1775-05-11; Potassium [Moles/volume] in Serum or Plasma 4.2 on 1775-05-11; Creatinine [Mass/volume] in Serum or Plasma 0.92 on 1775-10-19; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1770)/1.73 sq M 93 on 1775-10-19; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 1775-10-19; Albumin [Mass/volume] in Serum or Plasma 3.9 on 1775-07-13; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1775-10-28; Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 1.8 on 1775-10-19; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 1775-06-01; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 88 on 1775-06-01; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 1775-10-19; Neutrophils [#/volume] in Blood by Automated count 2.4 on 1775-09-08; Cholesterol [Mass/volume] in Serum or Plasma 196 on 1775-10-28; Cholesterol in HDL [Mass/volume] in Serum or Plasma 52 on 1775-10-28; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 118 on 1775-10-28; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 1775-10-28; Total score [AUDIT-C] 4 on 1775-10-28 [S]
Strengths and supports: Supports: a wide circle of friends who come to supper each week, and family nearby [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the sigmoid colon, suspected at presentation and confirmed by colonoscopic biopsy; synthetic modern diagnosis linked to the documented 1775 bowel disorder and its retrospective interpretation as colon cancer | active | confirmed | C18.7 | S — Synthetic diagnosis confirmed by biopsy and resection in the modern episode; the historical diagnosis remains a retrospective interpretation (R). |
| Iron deficiency anemia from chronic blood loss from the colon tumor | active | confirmed | D50.0 | S — Synthetic finding echoing the documented 'hemorrhage in the upper part of the intestines'; no blood count from his lifetime exists. |
| Hemangioma of the liver, 9 mm, segment VI; incidental finding characterized by MRI, not a metastasis | active | confirmed | D18.03 | S — Synthetic incidental finding; it addresses, and does not confirm, the unverified suggestion of liver spread. |
| Acute viral upper respiratory infection during adjuvant chemotherapy, without fever or neutropenia; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Oxaliplatin-induced sensory peripheral neuropathy, grade 1, fingertips and toe tips, without functional impairment | active | confirmed | G62.0 | S — Synthetic expected toxicity of adjuvant oxaliplatin. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1775-05-11 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1775-05-11 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 74 | fL | 80-100 fL | Low | S |
| 1775-05-11 | Leukocytes [#/volume] in Blood by Automated count | 7.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1775-05-11 | Platelets [#/volume] in Blood by Automated count | 438 | 10*3/uL | 150-400 10*3/uL | High | S |
| 1775-05-11 | Ferritin [Mass/volume] in Serum or Plasma | 9 | ng/mL | 30-400 ng/mL | Low | S |
| 1775-05-11 | Iron saturation [Mass Fraction] in Serum or Plasma | 6 | % | 20-50% | Low | S |
| 1775-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1775-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1775-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1775-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1770)/1.73 sq M | 91 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1775-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-55 U/L | Normal | S |
| 1775-05-11 | Albumin [Mass/volume] in Serum or Plasma | 3.8 | g/dL | 3.5-5 g/dL | Normal | S |
| 1775-05-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1775-06-01 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 6.4 | ng/mL | <=3 ng/mL | High | S |
| 1775-06-01 | Hemoglobin [Mass/volume] in Blood | 10.3 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1775-06-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 1775-06-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 8-48 U/L | Normal | S |
| 1775-06-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 88 | U/L | 40-129 U/L | Normal | S |
| 1775-06-01 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1775-07-13 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 2.2 | ng/mL | <=3 ng/mL | Normal | S |
| 1775-07-13 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1775-07-13 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 82 | fL | 80-100 fL | Normal | S |
| 1775-07-13 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1775-07-13 | Neutrophils [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1775-07-13 | Platelets [#/volume] in Blood by Automated count | 312 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1775-07-13 | Ferritin [Mass/volume] in Serum or Plasma | 186 | ng/mL | 30-400 ng/mL | Normal | S |
| 1775-07-13 | Iron saturation [Mass Fraction] in Serum or Plasma | 24 | % | 20-50% | Normal | S |
| 1775-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1775-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1770)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1775-07-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-55 U/L | Normal | S |
| 1775-07-13 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1775-07-13 | Albumin [Mass/volume] in Serum or Plasma | 3.9 | g/dL | 3.5-5 g/dL | Normal | S |
| 1775-07-13 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1775-10-19 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 1.8 | ng/mL | <=3 ng/mL | Normal | S |
| 1775-10-19 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1775-10-19 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 89 | fL | 80-100 fL | Normal | S |
| 1775-10-19 | Leukocytes [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1775-10-19 | Neutrophils [#/volume] in Blood by Automated count | 2.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1775-10-19 | Platelets [#/volume] in Blood by Automated count | 128 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1775-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1775-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1770)/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1775-10-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-55 U/L | Normal | S |
| 1775-10-19 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1775-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1775-09-08 | Leukocytes [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1775-09-08 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1775-09-08 | Hemoglobin [Mass/volume] in Blood | 12.1 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1775-09-08 | Platelets [#/volume] in Blood by Automated count | 156 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1775-10-28 | Cholesterol [Mass/volume] in Serum or Plasma | 196 | mg/dL | <=199 mg/dL | Normal | S |
| 1775-10-28 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 1775-10-28 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 118 | mg/dL | <=99 mg/dL | High | S |
| 1775-10-28 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 1775-10-28 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1775-10-28 | Total score [AUDIT-C] | 4 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1775-05-11 | Body height | 178 | cm | S |
| 1775-05-11 | Body weight | 88 | kg | S |
| 1775-05-11 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 1775-05-11 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1775-05-11 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1775-05-11 | Heart rate | 92 | /min | S |
| 1775-05-11 | Respiratory rate | 16 | /min | S |
| 1775-05-11 | Body temperature | 36.8 | Cel | S |
| 1775-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1775-06-01 | Body height | 178 | cm | S |
| 1775-06-01 | Body weight | 87.2 | kg | S |
| 1775-06-01 | Body mass index (BMI) [Ratio] | 27.5 | kg/m2 | S |
| 1775-06-01 | Systolic blood pressure | 130 | mm[Hg] | S |
| 1775-06-01 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1775-06-01 | Heart rate | 88 | /min | S |
| 1775-06-01 | Respiratory rate | 16 | /min | S |
| 1775-06-01 | Body temperature | 36.7 | Cel | S |
| 1775-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1775-07-13 | Body height | 178 | cm | S |
| 1775-07-13 | Body weight | 82.5 | kg | S |
| 1775-07-13 | Body mass index (BMI) [Ratio] | 26 | kg/m2 | S |
| 1775-07-13 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1775-07-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1775-07-13 | Heart rate | 78 | /min | S |
| 1775-07-13 | Respiratory rate | 16 | /min | S |
| 1775-07-13 | Body temperature | 36.6 | Cel | S |
| 1775-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1775-10-19 | Body height | 178 | cm | S |
| 1775-10-19 | Body weight | 81 | kg | S |
| 1775-10-19 | Body mass index (BMI) [Ratio] | 25.6 | kg/m2 | S |
| 1775-10-19 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1775-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1775-10-19 | Heart rate | 76 | /min | S |
| 1775-10-19 | Respiratory rate | 14 | /min | S |
| 1775-10-19 | Body temperature | 36.6 | Cel | S |
| 1775-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1775-09-08 | Body height | 178 | cm | S |
| 1775-09-08 | Body weight | 81.6 | kg | S |
| 1775-09-08 | Body mass index (BMI) [Ratio] | 25.8 | kg/m2 | S |
| 1775-09-08 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1775-09-08 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1775-09-08 | Heart rate | 84 | /min | S |
| 1775-09-08 | Respiratory rate | 16 | /min | S |
| 1775-09-08 | Body temperature | 37.3 | Cel | S |
| 1775-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1775-10-28 | Body height | 178 | cm | S |
| 1775-10-28 | Body weight | 81.4 | kg | S |
| 1775-10-28 | Body mass index (BMI) [Ratio] | 25.7 | kg/m2 | S |
| 1775-10-28 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1775-10-28 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1775-10-28 | Heart rate | 72 | /min | S |
| 1775-10-28 | Respiratory rate | 14 | /min | S |
| 1775-10-28 | Body temperature | 36.6 | Cel | S |
| 1775-10-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1775-05-11 | Primary care visit for three months of looser stools with dark blood, tiredness, and weight loss | finished | S |
| 1775-06-01 | Review of colonoscopy, biopsy, and staging CT; intravenous iron; medical oncology consultation | finished | S |
| 1775-07-13 | Review four weeks after laparoscopic sigmoid colectomy, before adjuvant chemotherapy | finished | S |
| 1775-10-19 | Review two weeks after completing adjuvant CAPOX and start of survivorship surveillance | finished | S |
| 1775-09-08 | Same-day sick visit for a head cold and cough during chemotherapy | finished | S |
| 1775-10-28 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Colonoscopy with biopsy, CT of the chest, abdomen, and pelvis, and baseline CEA for iron deficiency anemia with rectal bleeding in a man of 64 | completed | GL-AGA-IDA-2020, GL-NCCN-COLON-2025, GL-CMID-2026 | S |
| Medical oncology consultation to review staging, the indeterminate liver lesion, the order of treatment, and adjuvant therapy | completed | GL-NCCN-COLON-2025 | S |
| Intravenous ferric carboxymaltose before surgery to correct iron deficiency anemia, with ferritin and blood count rechecked six to eight weeks later | completed | GL-AGA-IDA-2020, GL-CMID-2026 | S |
| Laparoscopic sigmoid colectomy with lymph node dissection by the colorectal surgery team | completed | GL-NCCN-COLON-2025 | S |
| Three months (four cycles) of adjuvant CAPOX for low-risk stage III disease, after DPYD genotyping, with neuropathy, blood count, and diarrhea checks at every visit | completed | GL-IDEA-2018, GL-NCCN-COLON-2025, GL-CMID-2026 | S |
| Survivorship surveillance: history, examination, and CEA every 3 to 6 months for 2 years, then every 6 months to 5 years; CT of the chest, abdomen, and pelvis every 6 to 12 months for 5 years; colonoscopy one year after resection | completed | GL-CMID-2026, GL-ASCRS-2021, GL-ACS-CRC-2015 | S |
| Distress and depression screening at each visit, at least 150 minutes of activity a week, alcohol at or below one drink a day, and a written survivorship care plan | completed | GL-ACS-CRC-2015, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Complete diagnosis, staging, and curative resection within six weeks of presentation | 1775-07-13 | completed | Colonoscopy in eight days, staging complete in three and a half weeks, colectomy at five weeks | S |
| Replete iron stores before surgery and recover hemoglobin by the postoperative review | 1775-07-13 | completed | Ferritin 186 ng/mL and hemoglobin 12.4 g/dL four weeks after surgery, up from 9 ng/mL and 10.6 g/dL | S |
| Complete three months of adjuvant CAPOX with neuropathy no worse than grade 1 | 1775-10-19 | completed | Four cycles completed on schedule; grade 1 sensory neuropathy | S |
| Start survivorship surveillance with a written survivorship care plan | 1775-10-19 | completed | Survivorship care plan given; CEA 1.8 ng/mL; CT and colonoscopy dates set | S |